Prostate-specific antigen best practice policy-part I: Early detection and diagnosis of prostate cancer

Urology

Volumn 57, Issue 2, 2001, Pages 217-224

  Carroll, Peter ^a   Coley, Christopher ^b   McLeod, David ^c   Schellhammer, Paul ^d   Sweat, Greg ^e   Wasson, John ^f   Zietman, Anthony ^g   Thompson, Ian ^h,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD UNIVERSITY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d Eastern Virginia School of Medicine   (United States)

^e MAYO CLINIC   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h Mays Cancer Center at UT Health San Antonio   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; CANCER STAGING; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; GOOD CLINICAL PRACTICE; HUMAN; INTERMETHOD COMPARISON; MALE; MASS SCREENING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0035129450     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00993-6     Document Type: Article

References (59)

1. Cancer statistics, 1999
2. Early detection of prostate cancer. ; Part I: prior probability and effectiveness of tests
3. Prostate cancer; screening, diagnosis, and management
4. Prostate cancer; a current perspective
5. Screening for prostate cancer with prostate-specific antigen; an examination of the evidence
6. Localized prostate cancer; relationship of tumor volume to clinical significance for treatment of prostate cancer
7. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
8. Correlation of pathologic findings with progression after radical retropubic prostatectomy
9. Prediction of progression following radical prostatectomy; a multivariate analysis of 721 men with long-term follow-up
10. Results of conservative management of clinically localized prostate cancer
11. Histologic grading and staging of prostatic carcinoma
12. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
13. Re; is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup
14. Influence of capsular penetration on progression following radical prostatectomy; a study of 196 cases with long-term followup
15. Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates
16. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies
17. The definition and preoperative prediction of clinically insignificant prostate cancer
18. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer; a multi-institutional update
19. The role of detection in the rising incidence of prostate cancer
20. Prostatic carcinoma; incidence and location of unsuspected lymphatic metastases
21. Longitudinal screening for prostate cancer with prostate specific antigen
22. Defining clinically significant prostate cancer; pathologic criteria versus outcomes data
23. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II; early detection strategies
24. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination
25. Prostate-specific antigen and digital rectal examination in screening for prostate cancer; a community-based study
26. Screening for carcinoma of the prostate with prostate specific antigen
27. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer; results of a randomized, double-blind, placebo-controlled clinical trial
28. The effects of ejaculation on serum prostate-specific antigen (PSA)
29. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels
30. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination; enhancement of specificity with free PSA measurement
31. Prostate-specific antigen; current status
32. Influence of patient age on the serum PSA concentration; an important clinical observation
33. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease
34. Prostate-specific antigen as a screening test for prostate cancer
35. Age-specific reference ranges for serum prostate-specific antigen
36. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases
37. Prostate specific antigen; a decade of discovery-what we have learned and where we are going
38. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen
39. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men
40. Screening for prostate cancer
41. Screening for prostatic carcinoma with prostate specific antigen
42. Cancer surveillance series; interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
43. The European Screening Study for Prostate Cancer
44. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute
45. Prostate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer
46. Risk factors for prostate cancer
47. Epidemiologic evidence regarding predisposing factors to prostate cancer
48. Estimating treatment benefits for the elderly; the effect of competing risks
49. Mendelian inheritance of familial prostate cancer
50. Familial aspects of prostate cancer; a case control study
51. Familial patterns of prostate cancer; a case-control analysis
52. Family history and the risk of prostate cancer
53. Socioeconomic factors and cancer incidence among blacks and whites
54. Cancer statistics for African Americans
55. Low-grade, latent prostate cancer volume; predictor of clinical cancer incidence?
56. Prostatic cancer; mortality and incidence rates by race and social class